Impact of imipenem concentration in lung perfusate and tissue biopsy during clinical ex vivo lung perfusion (EVLP) of high-risk lung donors

Normothermic ex vivo lung perfusion (EVLP) limits organ donor shortage by potentially using high-risk donor lungs. Microbial burden reduction has been demonstrated after EVLP using antibiotic prophylaxis with imipenem. However, no data have been published on the clinical consequences of the potential residual bacterial burden. METHODS: Imipenem concentration was measured every hour (T0 to T6) in the lung perfusate and at the end of EVLP (Tf)in biopsies. The antimicrobial activity of perfusate at T1 and Tf against E. coli and K. pneumonia was evaluated. Lungs were distinguished: no bacterial species in recipients and donors (Donor-/Recipient-); bacterial species isolated from donors and not from recipients (Donor+/Recipient-); same bacterial species in both recipients and donors (Donor+/Recipient+). Interleukin 6 (IL6) and 8 (IL8) concentrations in lung perfusate, clinical pulmonary infection score (CPIS) and primary graft dysfunction (PGD) were evaluated. RESULTS: Imipenem concentration in perfusate decreased over time. T1 and Tf perfusates exhibited bactericidal activity against E. coli and K. pneumoniae. Overall, T1 perfusates yielded higher bactericidal titers (BTs) than Tf. Donor+/Recipient+ group (26% of cases) had higher IL6 and IL8 in perfusate and higher CPIS. CONCLUSIONS: Recipients with the same bacterial species isolated in their donors had higher risk of pulmonary inflammation and early post-transplant pneumonia. Improvements in antimicrobial strategies during EVLP are warranted to minimize the consequences of donor associated respiratory infection.